RS60886B1 - Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca - Google Patents
Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lancaInfo
- Publication number
- RS60886B1 RS60886B1 RS20201205A RSP20201205A RS60886B1 RS 60886 B1 RS60886 B1 RS 60886B1 RS 20201205 A RS20201205 A RS 20201205A RS P20201205 A RSP20201205 A RS P20201205A RS 60886 B1 RS60886 B1 RS 60886B1
- Authority
- RS
- Serbia
- Prior art keywords
- light chain
- human animals
- chain locus
- lambda light
- engineered immunoglobulin
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417845P | 2016-11-04 | 2016-11-04 | |
| US201762567932P | 2017-10-04 | 2017-10-04 | |
| EP17863293.1A EP3407709B9 (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| PCT/US2017/060006 WO2018128691A1 (en) | 2016-11-04 | 2017-11-03 | Non-human animals having an engineered immunoglobulin lambda light chain locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60886B1 true RS60886B1 (sr) | 2020-11-30 |
Family
ID=62025924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201205A RS60886B1 (sr) | 2016-11-04 | 2017-11-03 | Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca |
| RS20220669A RS63390B1 (sr) | 2016-11-04 | 2017-11-03 | Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220669A RS63390B1 (sr) | 2016-11-04 | 2017-11-03 | Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10820582B2 (sr) |
| EP (3) | EP4082334A1 (sr) |
| JP (4) | JP6884860B2 (sr) |
| KR (4) | KR102492433B1 (sr) |
| CN (2) | CN114369157A (sr) |
| AU (2) | AU2017391167B2 (sr) |
| BR (1) | BR112019008675A2 (sr) |
| CA (1) | CA3038720A1 (sr) |
| CY (1) | CY1123491T1 (sr) |
| DK (2) | DK3407709T3 (sr) |
| ES (2) | ES2823305T3 (sr) |
| HR (2) | HRP20220888T1 (sr) |
| HU (2) | HUE061980T2 (sr) |
| IL (2) | IL266282B2 (sr) |
| LT (2) | LT3407709T (sr) |
| MA (2) | MA44091A (sr) |
| MX (2) | MX2019005256A (sr) |
| PL (2) | PL3407709T3 (sr) |
| PT (2) | PT3766343T (sr) |
| RS (2) | RS60886B1 (sr) |
| RU (2) | RU2021129958A (sr) |
| SG (2) | SG11201903344XA (sr) |
| SI (2) | SI3766343T1 (sr) |
| WO (1) | WO2018128691A1 (sr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2863175A1 (en) * | 2012-02-01 | 2013-08-08 | Regeneron Pharamaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
| WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| SG11201903344XA (en) | 2016-11-04 | 2019-05-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| KR20200135397A (ko) | 2018-03-24 | 2020-12-02 | 리제너론 파마슈티칼스 인코포레이티드 | 펩티드-mhc 복합체에 대한 치료 항체를 생성하기 위한 유전적으로 변형된 비인간 동물, 이의 제조 방법 |
| MA52177A (fr) | 2018-03-26 | 2021-02-17 | Regeneron Pharma | Rongeurs humanisés pour tester des agents thérapeutiques |
| CA3103646C (en) | 2018-06-14 | 2023-06-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of engineered dh-dh rearrangement and uses thereof |
| US11464217B2 (en) | 2019-02-22 | 2022-10-11 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
| KR20220025839A (ko) * | 2019-07-01 | 2022-03-03 | 트리아니, 인코포레이티드 | 유전자이식 포유동물 및 이의 사용 방법 |
| KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| WO2022140219A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| MX2023007583A (es) | 2020-12-23 | 2023-07-07 | Regeneron Pharma | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2645698T3 (es) | 2001-11-30 | 2017-12-07 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| JP2007537704A (ja) * | 2003-07-15 | 2007-12-27 | セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド | ヒト化免疫グロブリン遺伝子座 |
| US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| EP3889265A1 (en) | 2008-09-30 | 2021-10-06 | Ablexis, LLC | Transgenic mice for the production of chimeric antibodies |
| CN112626117A (zh) * | 2008-12-18 | 2021-04-09 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| US20120204278A1 (en) * | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| EP2564695B1 (en) * | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
| CN103068993B (zh) | 2010-06-22 | 2016-01-06 | 瑞泽恩制药公司 | 杂交轻链小鼠 |
| SG10201913160QA (en) | 2011-02-25 | 2020-03-30 | Regeneron Pharma | Adam6 mice |
| HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| KR102186822B1 (ko) * | 2011-12-20 | 2020-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| BR112015019350A2 (pt) * | 2013-02-20 | 2017-08-22 | Regeneron Pharma | Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno |
| SG10201706741VA (en) | 2013-02-20 | 2017-10-30 | Regeneron Pharma | Genetic modification of rats |
| US9788534B2 (en) * | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| NL2013554B1 (en) * | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| KR102374379B1 (ko) | 2014-06-06 | 2022-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 표적화된 좌를 변형시키는 방법 및 조성물 |
| HUE049405T2 (hu) | 2014-06-23 | 2020-09-28 | Regeneron Pharma | Nukleáz-közvetített DNS-összeállítás |
| PL3221457T3 (pl) | 2014-11-21 | 2019-09-30 | Regeneron Pharmaceuticals, Inc. | Sposoby i kompozycje do celowanej modyfikacji genetycznej z zastosowaniem sparowanych przewodników RNA |
| WO2016100819A1 (en) | 2014-12-19 | 2016-06-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| SG11201903344XA (en) | 2016-11-04 | 2019-05-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
-
2017
- 2017-11-03 SG SG11201903344XA patent/SG11201903344XA/en unknown
- 2017-11-03 PL PL17863293T patent/PL3407709T3/pl unknown
- 2017-11-03 MA MA044091A patent/MA44091A/fr unknown
- 2017-11-03 ES ES17863293T patent/ES2823305T3/es active Active
- 2017-11-03 KR KR1020217034468A patent/KR102492433B1/ko active IP Right Grant
- 2017-11-03 RU RU2021129958A patent/RU2021129958A/ru unknown
- 2017-11-03 RU RU2019112589A patent/RU2757665C2/ru active
- 2017-11-03 MX MX2019005256A patent/MX2019005256A/es unknown
- 2017-11-03 JP JP2019522647A patent/JP6884860B2/ja active Active
- 2017-11-03 MA MA053935A patent/MA53935A/fr unknown
- 2017-11-03 HU HUE20180508A patent/HUE061980T2/hu unknown
- 2017-11-03 CA CA3038720A patent/CA3038720A1/en active Pending
- 2017-11-03 PL PL20180508.2T patent/PL3766343T3/pl unknown
- 2017-11-03 HR HRP20220888TT patent/HRP20220888T1/hr unknown
- 2017-11-03 RS RS20201205A patent/RS60886B1/sr unknown
- 2017-11-03 IL IL266282A patent/IL266282B2/en unknown
- 2017-11-03 HU HUE17863293A patent/HUE052087T2/hu unknown
- 2017-11-03 DK DK17863293.1T patent/DK3407709T3/da active
- 2017-11-03 LT LTEP17863293.1T patent/LT3407709T/lt unknown
- 2017-11-03 US US15/803,513 patent/US10820582B2/en active Active
- 2017-11-03 SI SI201731147T patent/SI3766343T1/sl unknown
- 2017-11-03 EP EP22164751.4A patent/EP4082334A1/en active Pending
- 2017-11-03 IL IL308197A patent/IL308197A/en unknown
- 2017-11-03 PT PT201805082T patent/PT3766343T/pt unknown
- 2017-11-03 CN CN202210050898.8A patent/CN114369157A/zh active Pending
- 2017-11-03 BR BR112019008675A patent/BR112019008675A2/pt unknown
- 2017-11-03 DK DK20180508.2T patent/DK3766343T3/da active
- 2017-11-03 WO PCT/US2017/060006 patent/WO2018128691A1/en active Application Filing
- 2017-11-03 KR KR1020247012338A patent/KR20240055863A/ko active Search and Examination
- 2017-11-03 PT PT178632931T patent/PT3407709T/pt unknown
- 2017-11-03 SI SI201730381T patent/SI3407709T1/sl unknown
- 2017-11-03 SG SG10201913483XA patent/SG10201913483XA/en unknown
- 2017-11-03 KR KR1020197015717A patent/KR102319069B1/ko active IP Right Grant
- 2017-11-03 CN CN201780067880.6A patent/CN109996441B/zh active Active
- 2017-11-03 RS RS20220669A patent/RS63390B1/sr unknown
- 2017-11-03 LT LTEP20180508.2T patent/LT3766343T/lt unknown
- 2017-11-03 KR KR1020237002504A patent/KR102658529B1/ko active IP Right Grant
- 2017-11-03 EP EP20180508.2A patent/EP3766343B1/en active Active
- 2017-11-03 ES ES20180508T patent/ES2915609T3/es active Active
- 2017-11-03 EP EP17863293.1A patent/EP3407709B9/en active Active
- 2017-11-03 AU AU2017391167A patent/AU2017391167B2/en active Active
-
2019
- 2019-05-03 MX MX2021010556A patent/MX2021010556A/es unknown
-
2020
- 2020-09-03 HR HRP20201403TT patent/HRP20201403T1/hr unknown
- 2020-09-24 US US17/031,367 patent/US20210029978A1/en active Pending
- 2020-10-29 CY CY20201101022T patent/CY1123491T1/el unknown
-
2021
- 2021-03-08 JP JP2021036180A patent/JP2021090455A/ja not_active Withdrawn
-
2022
- 2022-07-07 JP JP2022109658A patent/JP7386292B2/ja active Active
-
2023
- 2023-02-17 JP JP2023023312A patent/JP2023053400A/ja active Pending
-
2024
- 2024-01-31 AU AU2024200582A patent/AU2024200582A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266282A (en) | Non-human animals with a transgenic immunoglobulin light chain locus | |
| IL274797A (en) | Non-human animals with engineered immunoglobulin light chain and uses thereof | |
| HK1258227A1 (zh) | 具有修飾的免疫球蛋白重鏈序列的非人類動物 | |
| HK1250038A1 (zh) | 選擇結合抗原的輕鏈可變區的非人動物 | |
| DK2858487T3 (da) | Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci | |
| IL273749A (en) | Antibody-vegfr light chain fusion protein | |
| DK3129400T3 (da) | Ikke-humane dyr med humaniserede Fc-gamma-receptorer | |
| HK1247941A1 (zh) | 抗替代性輕鏈抗體 | |
| IL268049A (en) | Human antibodies from transgenic rodents with multiple immunoglobulin heavy chain LOCIs | |
| SG11201802698XA (en) | Transgenic rabbit with common light chain | |
| ITUB20160763A1 (it) | Imbracatura per cani guida perfezionata |